Ellerson Group Inc. ADV Purchases 15,722 Shares of DexCom, Inc. (NASDAQ:DXCM)

Ellerson Group Inc. ADV grew its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 28.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 70,035 shares of the medical device company’s stock after purchasing an additional 15,722 shares during the period. DexCom accounts for about 4.0% of Ellerson Group Inc. ADV’s investment portfolio, making the stock its 4th largest position. Ellerson Group Inc. ADV’s holdings in DexCom were worth $5,447,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of DXCM. Versant Capital Management Inc acquired a new stake in shares of DexCom in the fourth quarter worth approximately $25,000. Private Trust Co. NA boosted its position in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares during the last quarter. Larson Financial Group LLC boosted its position in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after acquiring an additional 137 shares during the last quarter. Heck Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter worth approximately $38,000. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of DexCom in the fourth quarter worth approximately $49,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Performance

Shares of DXCM opened at $77.84 on Friday. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a market cap of $30.42 billion, a price-to-earnings ratio of 54.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a fifty day moving average of $84.83 and a 200-day moving average of $76.99.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

DXCM has been the topic of several research analyst reports. Canaccord Genuity Group raised their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Citigroup raised their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Morgan Stanley raised their price target on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.